cannabidiol News
-
Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the American Society of Clinical Psychopharmacology Annual Meeting
Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced an oral podium presentation and a poster presentation at the American Society of Clinical Psychopharmacology Annual Meeting (ASCP 2022), being held May 31 – June 3, 2022, in Scottsdale, Ariz. A ...
-
Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel in Children and Adolescents with Fragile X Syndrome (FXS) at the 2022 Society of Biological Psychiatry Annual Meeting
Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, presented a poster at the 2022 Society of Biological Psychiatry (SOBP) Annual Meeting, held April 28-30, 2022, in New Orleans, La., and virtually. A copy of the poster is available on the Zynerba corporate website at ...
-
What is the Difference Between CBDA and CBD
What is the Difference Between CBDA and CBD? Now that CBD has been federally legal for a few years, you might be familiar with the differences between CBD and THC—the other most commonly known natural compound in the cannabis plant. (Most notably: THC produces a psychoactive feeling of being “high,” while CBD does not.) However, CBD and THC are far from being the only parts of ...
By Medcbdx
-
Zynerba Pharmaceuticals Announces Podium Presentation at the International Society for Autism Research Annual Meeting
Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced an oral podium presentation at the International Society for Autism Research Annual Meeting (INSAR 2022), being held both in-person and virtually May 11-14, 2022, from Austin, TX. A copy of the ...
-
Zynerba Pharmaceuticals Announces Presentation of Poster at the 2022 Society of Biological Psychiatry Annual Meeting
Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the presentation of a poster at the 2022 Society of Biological Psychiatry (SOBP) Annual Meeting, being held April 28-30, 2022, in New Orleans, La., and virtually. A copy of the poster will be made ...
-
Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel in Children and Adolescents with Fragile X Syndrome (FXS) at the International Society for Autism Research Annual Meeting
Data support the long-term safety and effectiveness of ZYGEL Greatest improvements seen in those with complete methylation of their fmr1 gene Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting an oral podium presentation at the International ...
-
Techcomp Products for Medical Marijuana
Medical marijuana uses the chemicals within the marijuana plant to help reduce pain and treat certain diseases. The plant contains more than 100 different chemicals called cannabinoids. Each one has a different effect on the body, with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) being the main chemicals used in ...
-
Zynerba Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights
Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel in patients with Fragile X syndrome (FXS); topline results expected second-half 2023 Topline results from Phase 2 trial of Zygel in patients with 22q11.2 deletion syndrome (22q) expected mid-year 2022 $69.7 million in cash and cash equivalents at March 31, 2022; Cash runway into second-half 2023 Zynerba ...
-
Diverse Biotech creates first new drug candidates and progresses them to Pre-Clinical Testing
Diverse Biotech, Inc. has announced it has successfully synthesized its first three new chemical entities (NCEs) and have progressed them into the pre-clinical testing starting with in vitro testing. These NCEs will be targeting basal cell carcinoma, pancreatic cancer, and glioblastoma with the ultimate future goal of establishing new standards of care for cancer patients. In addition, Diverse ...
-
CBD For Beginners: Everything you should Know About Cannabidiol
CBD For Beginners: Everything You Should Know About Cannabidiol You have likely already heard about the many potential benefits of including CBD in your wellness routine, but the idea of approaching CBD for beginners can be a little daunting. What is CBD? Is it addictive? How will it affect my body, and how is it consumed? For anyone just now considering CBD, there are tons of questions you may ...
By Medcbdx
-
Diverse Biotech establishes new Headquarters at the Pennsylvania Biotechnology Center
Diverse Biotech, Inc. has announced it has opened its Headquarters at the Pennsylvania Biotechnology Center which is a prominent incubator for small growing life sciences companies in Doylestown, PA. The PA Biotechnology Center contains a wealth of resources and a core support group of scientists and executives motivated to work collaboratively with their commercial colleagues on common research ...
-
Kannalife, Inc. Commences Trading on OTCQB Under Ticker Symbol "KLFE"
Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical company specializing in the research and development of cannabinoid therapeutics, brings proven cannabinoid R&D to the public by officially commencing trading on the OTC Markets under the ticker symbol “KLFE.” The Company previously had a registration statement on Form S-1 go ...
-
CanaQuest Launches Mentanine (R) (Cannabidiol + IP Formula) in the US via www.canaqueststore.com, Supported by Western University Pre-Clinical Trials Targeting Anxiety, Depression and PTSD
Canaquest Medical Corp (OTC Pink:CANQF) (the "Company" or "CanaQuest"), an award-winning, Clinical Stage/Life-Sciences company focused on drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors, today announced its US launch of all-natural Mentanine® (cannabidiol "CBD" + IP, Omega-3s, DHA, EPA formula) in ...
-
CanaQuest Achieves Statistically Significant Reduction of Seizures for Epilepsy Compared to Standard CBD
CANAQUEST MEDICAL CORP (OTC PINK:CANQF) (the "Company" or "CanaQuest"), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system (CNS), today announced Statistically Significant efficacy results from the Clinical Dose & Efficacy Study ("Study") conducted by Dr. W McIntyre Burnham, ...
-
Canaquest Launches Mentanine (Cannabidiol + IP Formula) in the US via www.canaqueststore.com, Supported by Western University Pre-Clinical Trials Targeting Anxiety, Depression and PTSD
Canaquest Medical Corp (OTC PINK:CANQF) (the “Company” or “CanaQuest“), an award-winning, Clinical Stage/Life-Sciences company focused on drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors, today announced its US launch of all-natural Mentanine (cannabidiol “CBD” + IP, Omega-3s, ...
-
Kannalife, Inc. Announces Results from Comparative UVB-Radiation Study on Atopidine Versus CBD
Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical medchem company specializing in the research and development of potent novel monotherapeutics, announced today that the studies performed on the Company’s patented compound, Atopidine™, suggest that Atopidine™ has outperformed cannabidiol (CBD) in preventing inflammatory ...
-
Kannalife, Inc. Announces Results from Comparative UVB-Radiation Study on Atopidine Versus CBD
DOYLESTOWN, Pa., April 14, 2020 (GLOBE NEWSWIRE) — Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical medchem company specializing in the research and development of potent novel monotherapeutics, announced today that the studies performed on the Company’s patented compound, Atopidine™, suggest that Atopidine™ has ...
-
Current Treatment Options and Research for Glioblastoma
Glioblastoma originates in the brain and typically does not spread to other parts of the body. It is a particularly difficult cancer to treat because tumors often overlap with healthy brain tissue making full surgical removal usually impossible. Treatments such as chemotherapy and radiation may slow the disease’s progression, but there is currently no cure. Glioblastoma Multiforme is the ...
-
Midweek Melbourne Money a winner for city businesses
The initiative, which offered a 30 per cent rebate on midweek meals in the city, drew in people from across Victoria, with 60 per cent of diners travelling from outside the City of Melbourne municipality. Diners visiting from outside the city spent an average of $43 more than city residents, with an average spend of $176. The average spend across the program was $158. The highest ...
-
Push to buy and make the city your local
This is Your Local showcases Melbourne's buzzing cultural scene, eclectic nightlife, beautiful greenspaces, exceptional employment opportunities and convenient amenities across print, digital and social media – all with the goal of encouraging new residents to make Melbourne 'their local'. Lord Mayor Sally Capp said the City of Melbourne is the ultimate 20 minute neighbourhood. ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you